Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | TKT | P29401 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11388566 | 0.82 | LMNA (0.70) | LMNATSHRALDH1A1HTT | |
| SCHEMBL7724215 | 0.81 | LMNA (0.69) | LMNACYP1A2TSHRTKTKDM4E | |
| SCHEMBL20618234 | 0.80 | LMNA (0.67) | LMNACYP1A2TSHRTKTKDM4E | |
| SCHEMBL11080074 | 0.79 | LMNA (0.66) | LMNATSHRKDM4EALDH1A1GAA | |
| SCHEMBL11284274 | 0.79 | LMNA (0.66) | LMNATSHRKDM4EALDH1A1GAA | |
| SCHEMBL18987265 | 0.79 | LMNA (0.65) | LMNACYP1A2TSHRTKTKDM4E | |
| SCHEMBL11752565 | 0.78 | LMNA (0.64) | LMNAKDM4EALDH1A1GAAHPGD | |
| SCHEMBL23748348 | 0.78 | LMNA (0.63) | LMNACYP1A2TSHRTKTKDM4E | |
| SCHEMBL12346332 | 0.78 | LMNA (0.63) | LMNACYP1A2TSHRTKTKDM4E | |
| SCHEMBL29895545 | 0.78 | LMNA (0.63) | LMNACYP1A2TSHRTKTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020040141-A1 | Preparation of 2-methyl-4-amino-5-aminomethylpyrimidine | BASF AKTIENGESELLSCHAFT (DE) | 2002-04-04 | — | — | US | claimed |
| US-6365740-B1 | REACTING 2-METHYL-4-AMINO-5-ALKOXYMETHYLPYRIMIDINE COMPOUND WITH AMMONIA IN PRESENCE OF CATALYST TO FORM 2-METHYL-4-AMINO-5-AMINOMETHYLPYRIMIDINE | BASF AKTIENGESELLSCHAFT (DE) | 2002-04-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040141-A1 | Preparation of 2-methyl-4-amino-5-aminomethylpyrimidine | DPYD, DNMT1, TPMT | LMNA 3550/4885CYP1A2 266/4885TSHR 4154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.